Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04070209 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Nov 2027 to Nov 2030
    • Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 10 to 11
    v6
  2. Site contacts updated at 10 of 10 sitesv5
  3. Study sites: 1 to 10
    • Eligibility criteria revised
    • Study description expanded, about 9 words
    v4
  4. Re-verified, no change to tracked fieldsv3
  5. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Jan 2020 to Oct 19, 2020
    • Study sites: 0 to 1
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is the first pilot phase II trial assessing the response of SBRT layered on Darolutamide (BAY1841788) on RPFS and deferring palliative second line systemic therapy in M0CRPC with oligoprogression.
Trial Details
NCT Number NCT04070209
Lead Sponsor Sir Mortimer B. Davis - Jewish General Hospital
Conditions
(from sponsor)		 Metastatic Prostate Cancer, Castration-resistant Prostate Cancer
Related terms Prostatic Neoplasms
Enrollment 66 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov